Archigen Biotech Limited
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Archigen Biotech Limited sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Archigen Biotech Limited: 2 sponsored US clinical trials, none currently recruiting.
Archigen Biotech Limited sponsors 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoma, Follicular, with 1 trials.
Mid-pack sponsor footprint
Archigen Biotech Limited is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Indexed trials (enrollment closed)
2 total, page 1 of 1
A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma
NCT02809053
PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis
NCT02819726
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Therapeutic Areas
How the Archigen Biotech Limited archive is shaped
2 indexed studies, none listed as recruiting (0% open); 2 completed (100%).
Phase mix: 1 late (III/IV) vs 1 early (I/II) (balanced across stages).
Top condition: Lymphoma, Follicular (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Archigen Biotech Limited: archived-pipeline peers nationwide
Peers matched on 2 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Archigen Biotech Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 archived trials
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Archigen Biotech Limited page
2 registered trials is a research-attention snapshot, not an endorsement of Archigen Biotech Limited or any single study.
- None of Archigen Biotech Limited's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Lymphoma, Follicular is the condition Archigen Biotech Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma, Follicular trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Archigen Biotech Limited pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.